My Treatment Approach: Treatment Selection for Relapsed/Refractory Follicular Lymphoma - Episode 2
Assessing Relapse: Clinical, Biological, and Patient-Centered Considerations
Together, they emphasize that relapse evaluation must go beyond radiographic progression alone. Some patients may demonstrate disease progression on imaging but remain clinically stable enough for continued surveillance. Others develop symptomatic relapse, requiring prompt intervention. The faculty describe the importance of understanding disease tempo, symptom burden, and patient goals when determining whether and when to initiate second-line therapy as components of personalized care.
The faculty address the pivotal question of how to evaluate patients who experience relapse. Dr. Mehta explains that the therapeutic landscape has expanded significantly compared with a decade ago, creating a need for more nuanced sequencing decisions. He reviews the growing number of FDA-approved options, including bispecific antibodies, CAR T-cell therapy, EZH2 inhibitors, and new combination regimens, and discusses how these advancements have reshaped treatment expectations.
A major focus of this segment is the concept of time to next treatment (TTNT), which Dr. Mehta identifies as one of the most meaningful clinical endpoints for patients. He outlines how TTNT can guide therapeutic choices and help clinicians weigh durability against toxicity and treatment burden. NP Bailey adds perspective on the importance of patient-related factors, including comorbidities, functional status, and lifestyle considerations that can influence therapy tolerability.
Related Content:
